Jonathan Alexander Chatzkel

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.

Christopher J. Hoimes, Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo et autres

us, es, it, ro, jp, il, de, fr (code pays fourni par la source)

Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.

Matthew D. Galsky, Begoña P. Valderrama, M. Maruzzo, A. Font Pous et autres

us, es, it, ro, jp, il, de, fr (code pays fourni par la source)

Updates on Clinical Trials and Molecular Characteristics of Locally Advanced and Oligometastatic Renal Cell Carcinoma

Temitope Ogunmola, Zeng Jin, Jeremy Kleberg, Tanzia Islam Tithi et autres

us, kr (code pays fourni par la source)

Pembrolizumab plus High-Dose IL-2 in Advanced Clear Cell Renal Cell Carcinoma: Six-Year Survival Outcomes and Molecular Signatures from a Phase 2 Trial

Jad Chahoud, Jeffrey S. Johnson, Michael J. Schell, Xiaoqing Yu et autres

us (code pays fourni par la source)

Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies

Jonathan Alexander Chatzkel, Joshua Linscott, G. Daniel Grass, Roger Li

us (code pays fourni par la source)

Near-complete resolution of tumour thrombus in a patient with advanced non-seminomatous germ cell tumour: a multidisciplinary approach without surgical intervention

Alicia Y. Hou, Akshay Mathavan, Akash Mathavan, Jonathan Alexander Chatzkel

us (code pays fourni par la source)

Clinical large language model to predict loss to follow up for oncology patients discharged to skilled nursing facilities.

Tianshi Liu, Ziyi Chen, Yonghui Wu, Jonathan Alexander Chatzkel et autres

us (code pays fourni par la source)

Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study.

Jad Chahoud, Bradley A. McGregor, Òscar Reig, Pedro C. Barata et autres

us, es, nz, fr, pl (code pays fourni par la source)

Erratum: Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

Thomas J. George, Ji‐Hyun Lee, David L. DeRemer, Peter J. Hosein et autres

Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms

Thomas J. George, Ji‐Hyun Lee, David L. DeRemer, Peter J. Hosein et autres

us (code pays fourni par la source)

Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic

Jonathan Alexander Chatzkel, Mayer Fishman, Brian Hemendra Ramnaraign, Padraic O’Malley et autres

us (code pays fourni par la source)

Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial.

Primo N. Lara, Stew Kroll, Jonathan Alexander Chatzkel, Deanna Teoh et autres

us (code pays fourni par la source)